Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib plus platinum-doublet chemotherapy versus platinum-doublet chemotherapy in first-line MET-amplified advanced non-squamous NSCLC
CTR20251038Phase 3Active
- Sponsor
- Beijing Purunao Biotechnology
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vebreltinib in non-small cell lung cancer (NSCLC), sponsored by Beijing Purunao Biotechnology. Started Jul 2025; status: active.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20251038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251038.